ArticleCureus2026
Methylprednisolone-Induced Delayed and Sustained Bradycardia in Multisystem Inflammatory Syndrome in Children.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic immunomodulation using pulse methylprednisolone is one of the cornerstones of management in multisystem inflammatory syndrome in children (MIS-C). This study examines whether bradycardia was possibly methylprednisolone-induced and if the risk and time taken to develop or recover from bradycardia depend on the dose or presence of shock.
methodsA longitudinal study of those with MIS-C who received methylprednisolone treatment was conducted. Baseline heart rate (HR) prior to starting treatment was documented, and heart rate was monitored every two hours by bedside cardiac monitors. Student's t-test was used to test the difference in means after log transformation if required. Kaplan-Meier curves were used to estimate the median time to onset and recovery of bradycardia, and Mood's two-sample test was used to test the difference in medians.
resultsOut of 89 children with MIS-C included in the study, most (84.3%) developed bradycardia after methylprednisolone administration, with a significant drop in heart rate irrespective of age. The median time of onset was 31.0 (interquartile range (IQR): 10.0-80.0) hours after the administration of methylprednisolone, and recovery occurred 57.0 (IQR: 14.0-202.0) hours later. This was not significantly different by dose or by the presence of shock. Although the proportion of bradycardia were similar across groups, the heart rate was significantly lower at bradycardia for those on pulse dose and those with shock when compared to those on conventional dose and those who did not have shock, respectively.
conclusionA high proportion of delayed and sustained bradycardia in children with MIS-C, irrespective of age, dose of methylprednisolone, or presence of shock, which is possibly induced by the steroid, was observed. The time to onset and the time to recovery were independent of the above factors. However, the heart rate at bradycardia varied significantly by dose and by the presence of shock.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.